Want to see GB:AMS full AI Analyst Report?
Top Page
Advanced Medical Solutions
(LSE:AMS)
Select Model
Select Model
Rating:63Neutral
Price Target:
299.00 p
▲(6.22% Upside)
Action:Reiterated
Date:08/07/26
The score is anchored by mixed financial performance: improving revenue and cash generation, but materially weaker margins/returns and higher leverage than prior years. Technicals are a clear positive with the stock in a strong uptrend, but the high P/E and modest dividend yield weigh on the overall rating.
Positive Factors
Revenue Momentum
Re-accelerating revenue in 2025 signals renewed top-line momentum that is durable if procedural volumes and product adoption continue. For a consumables-led medical device business, sustained revenue growth supports repeatable demand, distributor leverage and steadier OEM volumes over coming quarters.
Negative Factors
Profitability Compression
Material margin erosion reduces internal funding for growth and lowers returns to shareholders. If cost pressures, adverse mix, or pricing constraints persist, the company may struggle to restore historic profitability levels and will face tougher trade-offs between investment and margin recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Momentum
Re-accelerating revenue in 2025 signals renewed top-line momentum that is durable if procedural volumes and product adoption continue. For a consumables-led medical device business, sustained revenue growth supports repeatable demand, distributor leverage and steadier OEM volumes over coming quarters.
Read all positive factors
Advanced Medical Solutions (AMS) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£608.10M
Dividend Yield1.67%
Average Volume (3M)2.67M
Price to Earnings (P/E)60.8
Beta (1Y)1.11
Revenue Growth28.96%
EPS Growth39.58%
CountryUK
Employees1,800
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.05
Shares Outstanding219,604,170
10 Day Avg. Volume2,985,976
30 Day Avg. Volume2,668,033
Financial Highlights & Ratios
PEG Ratio1.19
Price to Book (P/B)1.82
Price to Sales (P/S)2.05
P/FCF Ratio21.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£275.00Price Target Upside-2.31% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.14
Revenue Forecast (FY)£245.05M
Advanced Medical Solutions Business Overview & Revenue Model
Company Description
Advanced Medical Solutions Group plc (AMS), along with its subsidiaries, specializes in the innovation, production, and worldwide distribution of advanced medical solutions. Its primary markets include wound treatment, surgical procedures, and wou...
How the Company Makes Money
AMS makes money primarily by selling medical devices and consumable products used in surgery and wound management. Key revenue streams include: (1) Branded product sales: revenue from AMS-owned products (e.g., tissue adhesives, internal sealants, ...
Advanced Medical Solutions Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
58
Neutral
Cash Flow
64
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 228.94M | 177.52M | 126.21M | 124.33M | 108.60M |
| Gross Profit | 108.78M | 82.77M | 70.14M | 68.62M | 56.12M |
| EBITDA | 43.39M | 29.68M | 31.40M | 34.94M | 31.55M |
| Net Income | 9.95M | 7.09M | 15.89M | 20.41M | 17.48M |
Balance Sheet | |||||
| Total Assets | 394.77M | 389.00M | 289.17M | 281.09M | 249.51M |
| Cash, Cash Equivalents and Short-Term Investments | 18.02M | 17.04M | 60.16M | 82.26M | 72.97M |
| Total Debt | 81.52M | 89.65M | 9.14M | 9.75M | 9.86M |
| Total Liabilities | 134.67M | 147.48M | 44.97M | 44.47M | 36.83M |
| Stockholders Equity | 258.79M | 240.78M | 244.20M | 236.62M | 212.68M |
Cash Flow | |||||
| Free Cash Flow | 21.39M | 12.67M | 2.50M | 17.12M | 23.95M |
| Operating Cash Flow | 28.75M | 16.73M | 12.35M | 27.08M | 30.41M |
| Investing Cash Flow | -13.54M | -67.15M | -20.27M | -12.70M | -6.41M |
| Financing Cash Flow | -14.92M | 5.48M | -13.62M | -5.70M | -4.41M |
Advanced Medical Solutions Technical Analysis
Positive
281.50
Price Trends
280.50
Positive
256.22
Positive
232.67
Positive
Market Momentum
1.21
Positive
58.72
Neutral
25.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AMS, the sentiment is Positive. The current price of 281.5 is above the 20-day moving average (MA) of 281.25, above the 50-day MA of 280.50, and above the 200-day MA of 232.67, indicating a neutral trend. The MACD of 1.21 indicates Positive momentum. The RSI at 58.72 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AMS.
Advanced Medical Solutions Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | £197.58M | 24.94 | 23.64% | 3.45% | 13.71% | 27.65% | |
70 Outperform | £4.43B | 48.65 | 8.40% | 2.45% | 1.94% | -43.71% | |
69 Neutral | £284.51M | 40.00 | 10.14% | 2.29% | 16.51% | 97.67% | |
64 Neutral | £957.64M | 58.48 | 2.22% | 0.63% | 4.54% | -34.92% | |
63 Neutral | £608.10M | 60.82 | 3.87% | 1.67% | 28.96% | 39.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £298.14M | -0.60 | -31.83% | ― | -5.89% | -310.69% |
* Healthcare Sector Average
GB:AMS
Advanced Medical Solutions
281.00
74.22
35.89%
GB:NIOX
Circassia Pharmaceuticals
67.60
-3.56
-5.01%
GB:CTEC
ConvaTec
228.20
-5.23
-2.24%
GB:PRTC
PureTech Health
121.60
3.60
3.05%
GB:SPI
Spire Healthcare
238.00
26.45
12.50%
GB:TSTL
Tristel
411.00
55.05
15.47%
Advanced Medical Solutions Corporate Events
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsShareholder Meetings
AMS publishes scheme document for H.B. Fuller cash takeover and AIM delisting
Positive
Jul 20, 2026
Advanced Medical Solutions Group PLC has published its formal scheme document for the recommended cash acquisition by H.B. Fuller Medical Adhesive Technologies, a wholly owned subsidiary of U.S.-listed H.B. Fuller Company. The deal, structured via...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
AMS posts higher H1 revenues and stays on track for full-year EBITDA
Positive
Jul 20, 2026
Advanced Medical Solutions expects to report half-year 2026 revenues of about £115.2 million, up from £110.8 million a year earlier, despite some orders slipping into July and de-stocking linked to its push to expand direct sales in Euro...
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
AMS Grants Executive LTIP Awards Ahead of H.B. Fuller Takeover
Positive
Jun 25, 2026
Advanced Medical Solutions has granted nil-cost share options to Chief Executive Officer Chris Meredith and Chief Financial Officer Eddie Johnson under its Long Term Incentive Plan, with 422,941 and 174,568 shares respectively subject to award. Th...
Business Operations and StrategyM&A Transactions
AMS gains more time as H.B. Fuller weighs possible takeover bid
Neutral
Jun 18, 2026
Advanced Medical Solutions Group, founded in 1991 and employing more than 1,800 people, manufactures surgical and wound care products across sites in Europe, Asia and the Middle East. The company has expanded through multiple acquisitions since 20...
Business Operations and StrategyStock BuybackDividendsFinancial DisclosuresShareholder Meetings
AMS Shareholders Back All AGM Resolutions, Bolstering Strategic Flexibility
Positive
Jun 17, 2026
Advanced Medical Solutions Group said all resolutions at its annual general meeting were approved by shareholders, including adoption of the financial statements, the remuneration report, auditor remuneration and the re-election or election of all...
M&A TransactionsShareholder Meetings
Advanced Medical Solutions AGM Held Amid Looming Takeover Deadline
Neutral
Jun 17, 2026
Advanced Medical Solutions Group, the UK-listed specialist in tissue-healing technologies with a broad portfolio of surgical and wound care products, will hold its Annual General Meeting today in London. The company operates globally through a mix...
Business Operations and StrategyM&A Transactions
Advanced Medical Solutions Confirms Unsolicited Takeover Approach From H.B. Fuller
Positive
May 21, 2026
Advanced Medical Solutions has disclosed that it received an unsolicited cash proposal from H.B. Fuller Company on 30 April 2026 for the entire issued and to be issued share capital, following recent press speculation. The company stressed there i...
Business Operations and Strategy
Advanced Medical Solutions Stays Independent as TA Associates Walks Away
Positive
May 18, 2026
Advanced Medical Solutions Group has responded to a statement from private equity firm TA Associates confirming it does not intend to make an offer for the company, placing TA under U.K. takeover rules that restrict a renewed approach. The AMS boa...
Business Operations and StrategyFinancial DisclosuresShareholder Meetings
Advanced Medical Solutions Publishes 2025 Annual Report and Sets June AGM
Positive
May 15, 2026
Advanced Medical Solutions Group has published its Annual Report and Accounts for the year ended 31 December 2025 and has dispatched these documents, together with the notice of its upcoming Annual General Meeting, to shareholders. The AGM is sche...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.